Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07643987
Diagnosis of Gestational Diabetes Based on a 50-gram Glucose ChallengeMethodist Health SystemCompleted
NCT07643987Completed
—
Diagnosis of Gestational Diabetes Based on a 50-gram Glucose ChallengeMethodist Health System
NCT07645924
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigraineKallyope Inc.Not Yet RecruitingPhase 3
NCT07645924Not Yet Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute T...Kallyope Inc.
NCT07645196
Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With DysmenorrheaVrije Universiteit BrusselNot Yet RecruitingNot Applicable
NCT07645196Not Yet Recruiting
Not Applicable
Effects of Physiotherapy on Ultrasound and Clinical Parameters in Women With Dys...Vrije Universiteit Brusse...
NCT07646418
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International UniversityRecruitingNot Applicable
NCT07646418Recruiting
Not Applicable
Combined Effects of LIRT-BFR Therapy in Post- Stroke PatientsRiphah International Univ...
NCT07645287
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Gilead SciencesNot Yet RecruitingPhase 2
NCT07645287Not Yet Recruiting
Phase 2
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologica...Gilead Sciences
NCT07646210
HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass SurgeryHELP Therapeutics Co., Ltd.Not Yet RecruitingPhase 1
NCT07646210Not Yet Recruiting
Phase 1
HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Byp...HELP Therapeutics Co., Lt...
NCT07644052
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderPleoPharma, Inc.RecruitingPhase 3
NCT07644052Recruiting
Phase 3
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cann...PleoPharma, Inc.
NCT07643766
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic DermatitisEnveda TherapeuticsNot Yet RecruitingPhase 2
NCT07643766Not Yet Recruiting
Phase 2
A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in...Enveda Therapeutics
NCT07645781
Cervical Stabilization Exercises IN Subacromial Impingement SyndromeCairo UniversityNot Yet RecruitingNot Applicable
NCT07645781Not Yet Recruiting
Not Applicable
Cervical Stabilization Exercises IN Subacromial Impingement SyndromeCairo University
NCT07646535
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary AldosteronismShenzhen Salubris Pharmaceuticals Co., Ltd.Not Yet RecruitingPhase 2
NCT07646535Not Yet Recruiting
Phase 2
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses i...Shenzhen Salubris Pharmac...
NCT07645495
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07645495Not Yet Recruiting
Not Applicable
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef University
NCT07645768
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alternative to Conventional Posterior Double Plating in Extra-Articular Distal Shaft Humeral FracturesCairo UniversityActive Not RecruitingNot Applicable
NCT07645768Active Not Recruiting
Not Applicable
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alter...Cairo University
NCT07644429
Biomechanical Characterisation of 3D Printed Comfort InsolesUniversity of PecsActive Not RecruitingNot Applicable
NCT07644429Active Not Recruiting
Not Applicable
Biomechanical Characterisation of 3D Printed Comfort InsolesUniversity of Pecs
NCT07644130
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere UniversityNot Yet RecruitingNot Applicable
NCT07644130Not Yet Recruiting
Not Applicable
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere University
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07643974
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDMedstar Health Research InstituteNot Yet RecruitingEarly Phase 1
NCT07643974Not Yet Recruiting
Early Phase 1
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDMedstar Health Research I...
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07646028
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLCNot Yet RecruitingPhase 1
NCT07646028Not Yet Recruiting
Phase 1
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLC
NCT07645131
Development of a Mobile Health Intervention to Support Functioning of Veterans With Substance Use DisordersVA Office of Research and DevelopmentNot Yet RecruitingNot Applicable
NCT07645131Not Yet Recruiting
Not Applicable
Development of a Mobile Health Intervention to Support Functioning of Veterans W...VA Office of Research and...
NCT07645625
Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical CancerUniversity Medical Center GroningenRecruitingPhase 4
NCT07645625Recruiting
Phase 4
Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical CancerUniversity Medical Center...
Result Breakdown
Not yet recruiting14 (70%)
Recruiting3 (15%)
Active, not recruiting2 (10%)
Completed1 (5%)
not_applicable8 (40%)
Phase 23 (15%)
Phase 13 (15%)
Not Specified2 (10%)
Phase 32 (10%)
Early Phase 11 (5%)
Phase 41 (5%)